Journal profile · Pharmacology & Pharmacy
Journal of Chemotherapy
ISSN 1120-009X · eISSN 1973-9478 · Maney Publishing · ITALY · Bimonthly · Founded 1989
Journal of Chemotherapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.16; subscription journal; APC charged, amount not published; median 118 days to acceptance (98 articles, last 24 months); community-reported acceptance: easy; 75 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Chemotherapy is published by Maney Publishing and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy and Pneumonia and Respiratory Infections, together about 37.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; Drug interactions in single or combined applications; Drug resistance to antimicrobial and anticancer drugs; Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; Pharmacogenetics and pharmacogenomics; Precision medicine in infectious disease therapy and in cancer therapy; Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry. The journal welcomes proposals for special issues and supplements, encouraging interested parties to get in touch to discuss their proposals.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editorial board by country: none in mainland China; most named Italy 48, United States 8, United Kingdom 6, France 3, Canada 3 (86 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology15.9%
- Antibiotics Pharmacokinetics and EfficacyMedicine14%
- Pneumonia and Respiratory InfectionsMedicine7.5%
- Antimicrobial Resistance in StaphylococcusMedicine7.2%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology6.2%
- Antibiotic Use and ResistanceImmunology and Microbiology4.5%
- Antifungal resistance and susceptibilityMedicine4.3%
- Urinary Tract Infections ManagementMedicine3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: Research Alert®
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.16LetPub ·
- Impact factor (publisher) 2025
- 2.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 1.9Publisher website ·
- CiteScore 2026-06
- 4.1LetPub ·
- CiteScore (publisher) 2025
- 4.1Publisher website ·
- SJR 2026-06
- 0.53LetPub ·
- SJR (publisher) 2025
- 0.53Publisher website ·
- SNIP 2026-06
- 0.55LetPub ·
- SNIP (publisher) 2025
- 0.55Publisher website ·
- h-index
- 45LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 1,436OpenAlex ·
- 2-year mean citedness
- 2.43OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 4.68%LetPub ·
Volume
- Articles per year
- 73LetPub ·
- Downloads per year (publisher)
- 81,000Publisher website ·
Articles by year OpenAlex count · 3,688 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 44 | 4 | 9 |
| 2025 | 75 | 9 | 100 |
| 2024 | 95 | 9 | 410 |
| 2023 | 73 | 11 | 351 |
| 2022 | 80 | 8 | 610 |
| 2021 | 84 | 8 | 777 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
118 daysMedian, submission to acceptance · P25–P75 85 days – 159 days
- Acceptance to online
- median 17 days (98 articles)
- Submission to online
- median 138 days
- Sample
- 98 articles with submission and acceptance dates (138 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 63%Publisher website ·
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 41 daysPublisher website ·
- Acceptance to publication
- 21 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted4
- brief communicationsThe Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemoth…Length not stated
- lettersThe Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemoth…Length not stated
- original research articlesThe Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemoth…Length not stated
- state-of-the-art reviewsThe Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemoth…Length not stated
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Hybrid open access journal, part of Taylor & Francis Open Select publishing program. Model summary
Journal of Chemotherapy is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Maney Publishing
- Country or region
- ITALY
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1989
- ISSN
- 1120-009X
- Electronic ISSN
- 1973-9478
- Latest issue on the website
- Volume 38, Issue 5 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Chemotherapy
What CAS zone is Journal of Chemotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Chemotherapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases / Oncology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Chemotherapy?
The latest impact factor listed by LetPub is 2.16; CiteScore 4.1, h-index 67.
How long does peer review take at Journal of Chemotherapy?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 118 days (interquartile range 85–159 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 63%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Chemotherapy based?
Of the 86 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (48), United States (8) and United Kingdom (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Chemotherapy?
According to LetPub and DOAJ records, Journal of Chemotherapy is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Journal of Chemotherapy open access, and what is the APC?
Journal of Chemotherapy is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .